AACR Conference on Targeting PI3K/mTOR Signaling in Cancer

Sally Church, PhD will be attending the American Association for Cancer Research (AACR) conference on the PI3K/mTOR pathway being held in San Francisco later this week, February 24-27.

Meetings such as this offer insight into the next generation of PI3K, Akt and mTOR inhibitors, and which compounds have promise for future clinical development.

If you are going to be in San Francisco for the meeting and would like to find out more about our capabilities and how we help commercial teams with new product development strategy, please contact us. It is always a pleasure to make new contacts.

, , , , , , , , , , , , , , , , , , ,

error: Content is protected !!